

SARS-CoV-2 spike protein is more stable, slower-changing than earlier version

March 30 2022, by Matt McGowan



Creative rendition of SARS-CoV-2 particles (not to scale). Credit: National Institute of Allergy and Infectious Diseases, NIH

New computational simulations of the behavior of SARS-CoV-1 and SARS-CoV-2 spike proteins prior to fusion with human cell receptors show that SARS-CoV-2, the virus that causes COVID-19, is more stable



and slower-changing than the earlier version that caused the SARS epidemic in 2003.

Severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2) have striking similarities, and researchers do not fully understand why the latter has been more infectious.

The spike proteins of each, which bind to host cell angiotensin converting enzyme 2, otherwise known as the human cell receptor, have been targeted as the potential source of the different transmissibility. Understanding the mechanistic details of the spike proteins prior to binding could lead to the development of better vaccines and medications.

The new finding does not necessarily mean that SARS-CoV-2 is more likely to bind to cell receptors, but it does mean that its spike protein has a better chance of effective binding.

"Once it finds the <u>cell receptor</u> and binds to it, the SARS-CoV-2 spike is more likely to stay bound until the rest of the necessary steps are completed for full attachment to the cell and initiation of cell entry," said Mahmoud Moradi, associate professor of chemistry and biochemistry in the Fulbright College of Arts and Sciences.

To determine differences in conformational behavior between the two versions of the virus, Moradi's research team performed an extensive set of equilibrium and nonequilibrium simulations of the molecular dynamics of SARS-CoV-1 and SARS-CoV-2 spike proteins, leading up to binding with cell <u>angiotensin</u> converting enzyme 2. The 3D simulations were done on a microsecond-level, using computational resources provided by the COVID-19 High Performance Computing Consortium.



Equilibrium simulations allow the models to evolve spontaneously on their own time, while nonequilibrium simulations use external manipulation to induce the desired changes in a system. The former is less biased, but the latter is faster and allows for many more simulations to run. Both methodological approaches provided a consistent picture, independently demonstrating the same conclusion that the SARS-CoV-2 spike proteins were more stable.

The models revealed other important findings, namely that the <u>energy</u> <u>barrier</u> associated with activation of SARS-CoV-2 was higher, meaning the binding process happened slowly. Slow activation allows the spike protein to evade human immune response more efficiently, because remaining in an inactive state longer means the virus cannot be attacked by antibodies that target the receptor binding domain.

Researchers understand the importance of the so-called receptor-binding domain, or RBD, which is the critical part of a virus that allows it to dock to human cell receptors and thus gain entry into cells and cause infection. Models produced by Moradi's team confirm the importance of the receptor-binding domain but also suggest that other domains, such as the N-terminal domain, could play a crucial role in the different binding behavior of SARS-CoV-1 and -2 spike proteins.

The N-terminal domain of a protein is a domain located at the Nterminus or simply the start of the polypeptide chain, as opposed to the C-terminus, which is the end of the chain. Though it is near the receptorbinding domain and is known to be targeted by some antibodies, function of the N-terminal domain in SARS-CoV-1 and -2 spike proteins is not completely understood. Moradi's team is the first to find evidence for potential interaction of the N-terminal domain and the receptor binding domain.

"Our study sheds light on the conformational dynamics of the SARS-



CoV-1 and SARS-CoV-2 spike proteins," Moradi said. "Differences in the dynamic behavior of these <u>spike proteins</u> almost certainly contribute to differences in transmissibility and infectivity."

More information: Vivek Govind Kumar et al, Prefusion Spike Protein Conformational Changes Are Slower in SARS-CoV-2 than in SARS-CoV-1, *Journal of Biological Chemistry* (2022). DOI: <u>10.1016/j.jbc.2022.101814</u>

Provided by University of Arkansas

Citation: SARS-CoV-2 spike protein is more stable, slower-changing than earlier version (2022, March 30) retrieved 28 January 2023 from <u>https://medicalxpress.com/news/2022-03-sars-cov-spike-protein-stable-slower-changing.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.